Phase I Two-Year Follow Up Study Results Released

Tuesday, December 15, 2020

In our Phase I two-year follow up study, our clinical team monitored the Phase I patients for two additional years after their treatment. Our results showed that there were no long-term side effects from the MSC-NP therapy. Importantly, a subset of patients showed sustained clinical improvement two years after treatment. These encouraging findings suggest that some of the clinical benefits of MSC-NP may be long-lasting.

CLICK HERE or the link below to read more: 

News Archive


Tisch MS Research Center of New York

521 West 57th Street
4th Floor
New York, NY 10019
(646) 557-3900

Privacy Policy


Support Tisch MS

Support Tisch MS and our innovative research leading to treatments that improve the lives of patients.